<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03339700</url>
  </required_header>
  <id_info>
    <org_study_id>INCMNSZ REF 2235</org_study_id>
    <nct_id>NCT03339700</nct_id>
  </id_info>
  <brief_title>Addition of Gemcitabine to Pre Allo-HSCT Conditioning for Acute Lymphoblastic Leukemia</brief_title>
  <official_title>Addition of Gemcitabine to the Standard Reduced BUCY2 Pre Allogeneic Hematopoietic Stem Cell Transplantation Conditioning for Acute Lymphoblastic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of the project is to evaluate the disease free survival and overall survival
      in patients diagnosed with acute lymphoblastic leukemia undergoing allogeneic hematopoietic
      stem cell transplantation (allo-HSCT) adding gemcitabine to our standard conditioning regimen
      based on two alkylating drugs (reduced BUCY 2).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the last decade, HSCT has become an efficient strategy for the treatment of high risk
      acute lymphoblastic leukemias. Lymphoid acute leukemias (ALL) are considered malignant clonal
      diseases of the hematopoietic stem cells, and represent a therapeutic challenge due to the
      high relapse rate and mortality using conventional chemotherapy regimens. Many studies have
      shown a decrease in relapse and an increase in overall survival with allogeneic HSCT,
      however, despite the fact that results in ALL have improved in the past years, achieving
      complete remission (CR) in approximately 75% of the patients, the relapse rate remains high
      and long term survival is lower than 50% depending on age and disease characteristics. On the
      other hand, it has been stated that relapse is higher when an allo-HSCT is performed in
      second CR, obtaining poorer results compared to performing HSCT in first CR, although better
      than chemotherapy alone (87% probability of relapse).

      It is necessary to implement strategies that increase efficiency of pre transplant
      conditioning regimens in patients diagnosed with ALL undergoing an allo-HSCT in order to
      reduce relapse and increase overall survival. Our hypothesis is that adding gemcitabine to
      our standard reduced BUCY 2 conditioning regimen in patients with ALL undergoing an allo-HSCT
      will have an improved relapse free survival as well as better overall survival, because it
      has been demonstrated in other malignant hematological diseases that gemcitabine plus two
      alkylating agents, facilitates synergism with busulfan and melphalan, inhibiting the DNA
      damage repair and causing a higher cytotoxic effect.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 15, 2017</start_date>
  <completion_date type="Anticipated">December 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2018</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Free Survival</measure>
    <time_frame>3 years</time_frame>
    <description>Time between transplantation and relapse or last follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>5 years</time_frame>
    <description>Time between transplantation and dead or last follow-up</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Acute Lymphoblastic Leukemia, Adult</condition>
  <arm_group>
    <arm_group_label>Unique</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive reduced BUCY 2 conditioning regimen, consisting in the administration of two medications: Busulfan and Cyclophosphamide Plus: Gemcitabine. Then they will undergo an Allogeneic Hematopoietic Stem Cell Transplantation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>4800mg/m2, intravenous, divided 4 days, 1200mg/m2/day, during days -5 to -2</description>
    <arm_group_label>Unique</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>12mg/kg, ORAL, divided in 4 days, 3mg/kg/day ORAL, during days -7 to -4.</description>
    <arm_group_label>Unique</arm_group_label>
    <other_name>Myleran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>80mg/kg, Intravenous (IV), divided in 2 days, 40mg/kg/day IV, during days -3 and -2.</description>
    <arm_group_label>Unique</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>Bone Marrow HSC (allogeneic HSCT) transfusion, day 0</description>
    <arm_group_label>Unique</arm_group_label>
    <other_name>Allogeneic Bone Marrow Transplantation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of ALL in 1st or 2nd complete remission, candidates to HSCT

          -  Hb ≥ 10 g/dl, Absolute Neutrophil Count ≥ 1 x 103/mm3, and Platelets ≥ 100,000 /µL

          -  ECOG ≤2 oR Karnofsky ≥80%

          -  Signed Informed Consent

          -  FEVI &gt;40%

          -  Normal liver function enzyme tests

          -  Preserved renal function

        Exclusion Criteria:

          -  Patients not willing to participate or to sign the informed consent

          -  Patients who do not meet the inclusion criteria

          -  ALL in 3rd complete remission
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eucario M Leon Rodriguez, M.D.</last_name>
    <phone>525554870900</phone>
    <phone_ext>2255</phone_ext>
    <email>eucarios@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Monica M Rivera Franco, M.D.</last_name>
    <phone>525554870900</phone>
    <phone_ext>2719</phone_ext>
    <email>monrif90d@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</name>
      <address>
        <city>Mexico City</city>
        <state>Distrito Federal</state>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eucario Leon Rodriguez, M.D.</last_name>
      <phone>525554870900</phone>
      <phone_ext>2255</phone_ext>
      <email>eucarios@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Monica M Rivera Franco, M.D.</last_name>
      <phone>525554870900</phone>
      <phone_ext>2719</phone_ext>
      <email>monrif90d@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <reference>
    <citation>Nieto Y, Thall P, Valdez B, Andersson B, Popat U, Anderlini P, Shpall EJ, Bassett R, Alousi A, Hosing C, Kebriaei P, Qazilbash M, Frazier E, Gulbis A, Chancoco C, Bashir Q, Ciurea S, Khouri I, Parmar S, Shah N, Worth L, Rondon G, Champlin R, Jones RB. High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies. Biol Blood Marrow Transplant. 2012 Nov;18(11):1677-86. doi: 10.1016/j.bbmt.2012.05.011. Epub 2012 May 27.</citation>
    <PMID>22643322</PMID>
  </reference>
  <reference>
    <citation>Peters GJ, Ruiz van Haperen VW, Bergman AM, Veerman G, Smitskamp-Wilms E, van Moorsel CJ, Kuiper CM, Braakhuis BJ. Preclinical combination therapy with gemcitabine and mechanisms of resistance. Semin Oncol. 1996 Oct;23(5 Suppl 10):16-24. Review.</citation>
    <PMID>8893877</PMID>
  </reference>
  <reference>
    <citation>Wang E, Gulbis A, Hart JW, Nieto Y. The emerging role of gemcitabine in conditioning regimens for hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2014 Sep;20(9):1382-9. doi: 10.1016/j.bbmt.2014.04.025. Epub 2014 May 9.</citation>
    <PMID>24816580</PMID>
  </reference>
  <reference>
    <citation>Anderlini P, Saliba RM, Ledesma C, Chancoco C, Alousi AM, Shpall EJ, Popat UR, Hosing CM, Khouri IF, Nieto Y, Ciurea S, Younes A, Fanale MA, Acholonu S, Valverde R, Champlin RE. Gemcitabine, fludarabine and melphalan as a reduced-intensity conditioning regimen for allogeneic stem cell transplant in relapsed and refractory Hodgkin lymphoma: preliminary results. Leuk Lymphoma. 2012 Mar;53(3):499-502. doi: 10.3109/10428194.2011.615427. Epub 2011 Oct 24.</citation>
    <PMID>21859247</PMID>
  </reference>
  <reference>
    <citation>Matsuda A, Sasaki T. Antitumor activity of sugar-modified cytosine nucleosides. Cancer Sci. 2004 Feb;95(2):105-11. Review.</citation>
    <PMID>14965358</PMID>
  </reference>
  <reference>
    <citation>Spasokoukotskaja T, Arnér ES, Brosjö O, Gunvén P, Juliusson G, Liliemark J, Eriksson S. Expression of deoxycytidine kinase and phosphorylation of 2-chlorodeoxyadenosine in human normal and tumour cells and tissues. Eur J Cancer. 1995;31A(2):202-8.</citation>
    <PMID>7718326</PMID>
  </reference>
  <reference>
    <citation>Braakhuis BJ, Ruiz van Haperen VW, Boven E, Veerman G, Peters GJ. Schedule-dependent antitumor effect of gemcitabine in in vivo model system. Semin Oncol. 1995 Aug;22(4 Suppl 11):42-6.</citation>
    <PMID>7481844</PMID>
  </reference>
  <reference>
    <citation>Csoka K, Liliemark J, Larsson R, Nygren P. Evaluation of the cytotoxic activity of gemcitabine in primary cultures of tumor cells from patients with hematologic or solid tumors. Semin Oncol. 1995 Aug;22(4 Suppl 11):47-53.</citation>
    <PMID>7481845</PMID>
  </reference>
  <reference>
    <citation>Plunkett W, Huang P, Searcy CE, Gandhi V. Gemcitabine: preclinical pharmacology and mechanisms of action. Semin Oncol. 1996 Oct;23(5 Suppl 10):3-15. Review.</citation>
    <PMID>8893876</PMID>
  </reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 8, 2017</study_first_submitted>
  <study_first_submitted_qc>November 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2017</study_first_posted>
  <last_update_submitted>November 8, 2017</last_update_submitted>
  <last_update_submitted_qc>November 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Busulfan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

